address1,address2,city,zip,country,phone,website,industry,industryKey,industryDisp,sector,sectorKey,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,executiveTeam,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,tradeable,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,52WeekChange,SandP52WeekChange,quoteType,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,symbol,language,region,typeDisp,quoteSourceName,triggerable,customPriceAlertConfidence,regularMarketChangePercent,regularMarketPrice,shortName,longName,marketState,market,esgPopulated,hasPrePostMarketData,firstTradeDateMilliseconds,regularMarketChange,regularMarketDayRange,fullExchangeName,averageDailyVolume3Month,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekChangePercent,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,isEarningsDateEstimate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,sourceInterval,exchangeDataDelayedBy,averageAnalystRating,cryptoTradeable,corporateActions,regularMarketTime,exchange,messageBoardId,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,trailingPegRatio
Förändringens gata 10,Mölndal,Gothenburg,431 53,Sweden,46 768 66 77 87,https://www.cerenoscientific.com,Drug Manufacturers - Specialty & Generic,drug-manufacturers-specialty-generic,Drug Manufacturers - Specialty & Generic,Healthcare,healthcare,Healthcare,"Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic, and anti-thrombotic properties. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I for the treatment of cardiovascular, pulmonary diseases, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases, such as anti phospholipid syndrome. The company has a collaboration agreement with the University of Michigan for the preclinical development program of CS585 and CS014, are preclinical drug candidate for cardiovascular diseases; and Abbott for use of CardioMEMS HF System. Cereno Scientific AB (publ) was incorporated in 2012 and is headquartered in Gothenburg, Sweden.",10,"[{'maxAge': 1, 'name': 'Mr. Sten R. Sorensen', 'age': 65, 'title': 'CEO & Director', 'yearBorn': 1959, 'fiscalYear': 2024, 'totalPay': 5087000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Eva  Jagenheim', 'age': 58, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bjorn  Dahlof FACC, FESC, M.D., Ph.D.', 'age': 71, 'title': 'Chief Scientific Officer', 'yearBorn': 1953, 'fiscalYear': 2024, 'totalPay': 96000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tove  Bergenholt', 'age': 36, 'title': 'Head of IR & Communications', 'yearBorn': 1988, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Fredrik  Frick', 'age': 51, 'title': 'Head of Clinical Operations', 'yearBorn': 1973, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Nicholas  Oakes', 'age': 63, 'title': 'Head of Preclinical Development', 'yearBorn': 1961, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rahul  Agrawal M.D.', 'age': 59, 'title': 'Chief Medical Officer & Head of R&D', 'yearBorn': 1965, 'fiscalYear': 2024, 'exercisedValue': 0, 'unexercisedValue': 0}]",1735603200,[],86400,2,9.44,9.27,9.27,9.83,9.44,9.27,9.27,9.83,0.0,-0.049,-44.904766,712737,712737,1370070,1243261,1243261,9.46,9.49,2656450048,4.7,11.9,35.086212,9.9273,6.660435,0.0,0.0,SEK,False,2962673408,-1.44095,239922642,280980000,0.27156,0.0678,284835008,0.593,15.902193,1735603200,1767139200,1743379200,-109097192,-0.4,-0.21,39.131,-38.428,0.38925683,0.10500872,EQUITY,9.43,0.0,strong_buy,77000184,0.273,-77096224,180400000,2.563,2.645,75712080,108.02,0.258,-0.14965999,-0.59292,75712080,-141652176,-111470216,-0.24,1.0,-1.01828,-1.0679799,SEK,CRNO-B.ST,en-US,US,Equity,Delayed Quote,True,HIGH,-0.10592453,9.43,Cereno Scientific AB ser. B,Cereno Scientific AB (publ),PREPRE,se_market,False,False,1466578800000,-0.009999275,9.27 - 9.83,Stockholm,1370070,4.7300005,1.0063832,4.7 - 11.9,-2.4699993,-0.20756297,38.925682,1756292340,1756292340,1756292340,False,-0.4,-0.21,-0.34,-27.735294,-0.49730015,-0.0500942,2.769565,0.41582343,15,0,0.0 - Strong Buy,False,[],1751988587,STO,finmb_216025020,Europe/Stockholm,CEST,7200000,
